SBIR/STTR Research Award

A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment

Award identifier 6a07bdc11277967cacde842f231174b830fe05889fddb6a3d728d606f8be464cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,647,446

Program and phase

SBIR · Phase II

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
P2D, INC
Proposal award date
2017-09-15
Contract end date
2021-05-31
UEI
KX3EAX2JEMV8
Solicitation number
PAR16-027
Topic code
NIA

Research abstract

ABSTRACT The goal of this proposal is to develop tumor necrosis factorTNFinhibiting compounds as neuroprotectant drugs for treating Alzheimer s diseaseADCurrent FDA approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progressionThusa critical need exists for a novel AD treatment directed towards AD pathophysiologyRecent studies implicate the neuroinflammatory cytokine TNFas a key mediator in ADassociated neurodegenerative pathologyMultiple preclinical and clinical studies indicate that TNFis adruggablemolecular target to modify the course of AD progressionPreliminary Studies demonstrate that our lead compound shows potent TNFinhibition in vitroOur PhaseSBIR studies demonstrate that our small molecule TNFinhibitor administered orally every day formonths significantly improved cognitive function in the triple transgenicxTgAD mouse modelOur compound also modulated brain TNFprotein levels and halted the progress of AD associated neuropathology including Aplaques and neurofibrillary tangles as assessed by immunohistological stainingNo morbiditymortality or any obvious side effects were observed despite the long term oral daily treatment regimen with our compoundTaken togetherthese data strongly suggest that our lead compound is an excellent anti AD drug candidateThe proposed studies are following up on recently awarded phaseSBIR where we are performing several key FDA required IND studiesThe proposed CRP grant studies will build on the phaseSBIR studies to lead to an IND submissionKey Aims include large animal safety toxicology studies and preparation for Pre IND meeting with the FDA PROJECT NARRATIVE Alzheimer s DiseaseADis a significant neurological problem affecting nearlymillion of our senior U ScitizensThe present research aims to develop a compound that targets the underlying neuroinflammation in AD to modify disease progression and improve cognitive function

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

52 SBIR/STTR records share this UEI (2001–2021). Reported award amounts total $21,593,440. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.